All levels are marked in the chart only.
Cadila Healthcare can begin a new bull run on technical levels......analysis is also backed by news of Virafin(an antiviral produced by Cadila Healthcare) being given emergency approval for treatment of moderate COVID-19 patients.
Volume has also increased drastically.
Cadila has also given closing above a trendline which was previously acting as resistance for the price to move up.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在
使用條款閱讀更多資訊。